Celgene
Abecma
Manufacturer:
Celgene
Name:
Abecma
HCPCS Code Descriptor:
Idecabtagene vicleucel, up to 460 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Category:
Q Code
HCPCS:
Q2055
NDC(s):
59572-0515-02, 59572-0515-03, 59572-0515-01
Primary Type:
Oncology
Generic Status:
Single-Source
Route of Administration:
Intravenous
About:
Abecma is an Oncology drug manufactured by Celgene and administered via the Intravenous route of administration. The Q Code: Q2055 is aligned to the drug Abecma.